Truist has adjusted its price target for iRhythm Technologies (IRTC, Financial), reducing it from $145 to $120, while maintaining a Buy rating. This revision comes as part of a broader analysis anticipating the company's first-quarter performance in the medical technology sector.
Despite some market turbulence, particularly related to tariffs, iRhythm's revenue and earnings are expected to be more resilient compared to other sub-sectors. This relative stability is likely to keep investors engaged in iRhythm, even as the industry faces economic challenges.
Looking ahead, Truist has indicated a cautious outlook for 2025. Companies, including iRhythm, may start incorporating macroeconomic uncertainties into their financial models, reflecting a more guarded approach to future growth predictions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for iRhythm Technologies Inc (IRTC, Financial) is $131.91 with a high estimate of $152.00 and a low estimate of $104.00. The average target implies an upside of 33.66% from the current price of $98.69. More detailed estimate data can be found on the iRhythm Technologies Inc (IRTC) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, iRhythm Technologies Inc's (IRTC, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for iRhythm Technologies Inc (IRTC, Financial) in one year is $164.54, suggesting a upside of 66.72% from the current price of $98.69. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the iRhythm Technologies Inc (IRTC) Summary page.
